These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Pentacycloundecane lactam vs lactone norstatine type protease HIV inhibitors: binding energy calculations and DFT study. Honarparvar B; Pawar SA; Alves CN; Lameira J; Maguire GE; Silva JR; Govender T; Kruger HG J Biomed Sci; 2015 Feb; 22(1):15. PubMed ID: 25889635 [TBL] [Abstract][Full Text] [Related]
7. Pentacycloundecane derived hydroxy acid peptides: a new class of irreversible non-scissile ether bridged type isoster as potential HIV-1 wild type C-SA protease inhibitors. Karpoormath R; Sayed Y; Govender P; Govender T; Kruger HG; Soliman MES; Maguire GEM Bioorg Chem; 2012 Feb; 40(1):19-29. PubMed ID: 21982718 [TBL] [Abstract][Full Text] [Related]
8. Comparative studies on inhibitors of HIV protease: a target for drug design. Jayaraman S; Shah K In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129 [TBL] [Abstract][Full Text] [Related]
9. Design, biologic evaluation, and SAR of novel pseudo-peptide incorporating benzheterocycles as HIV-1 protease inhibitors. He M; Zhang H; Yao X; Eckart M; Zuo E; Yang M Chem Biol Drug Des; 2010 Aug; 76(2):174-80. PubMed ID: 20572811 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of triazolamers as active site inhibitors of HIV-1 protease. Jochim AL; Miller SE; Angelo NG; Arora PS Bioorg Med Chem Lett; 2009 Nov; 19(21):6023-6. PubMed ID: 19800230 [TBL] [Abstract][Full Text] [Related]
11. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease. Lu D; Sham YY; Vince R Bioorg Med Chem; 2010 Mar; 18(5):2037-48. PubMed ID: 20138769 [TBL] [Abstract][Full Text] [Related]
12. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach. Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity. Wei Y; Ma CM; Hattori M Eur J Med Chem; 2009 Oct; 44(10):4112-20. PubMed ID: 19493591 [TBL] [Abstract][Full Text] [Related]
14. Active site binding modes of dimeric phloroglucinols for HIV-1 reverse transcriptase, protease and integrase. Gupta P; Kumar R; Garg P; Singh IP Bioorg Med Chem Lett; 2010 Aug; 20(15):4427-31. PubMed ID: 20594846 [TBL] [Abstract][Full Text] [Related]
15. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions. Seibold SA; Cukier RI Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840 [TBL] [Abstract][Full Text] [Related]
16. Oximinoarylsulfonamides as potent HIV protease inhibitors. Yeung CM; Klein LL; Flentge CA; Randolph JT; Zhao C; Sun M; Dekhtyar T; Stoll VS; Kempf DJ Bioorg Med Chem Lett; 2005 May; 15(9):2275-8. PubMed ID: 15837308 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of commercial inhibitors against subtype F HIV-1 protease. Krauchenco S; Martins NH; Sanches M; Polikarpov I J Enzyme Inhib Med Chem; 2009 Jun; 24(3):638-45. PubMed ID: 18825538 [TBL] [Abstract][Full Text] [Related]
18. Analysis of HIV wild-type and mutant structures via in silico docking against diverse ligand libraries. Chang MW; Lindstrom W; Olson AJ; Belew RK J Chem Inf Model; 2007; 47(3):1258-62. PubMed ID: 17447753 [TBL] [Abstract][Full Text] [Related]
19. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Muzammil S; Ross P; Freire E Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275 [TBL] [Abstract][Full Text] [Related]